Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on March 6, 2024, covering events occurring on February 29, 2024, and March 4, 2024. The Company is a Delaware corporation with its principal executive offices in Carlsbad, California, and its common stock trades on the Nasdaq Capital Market under the symbol "PALI."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
- Board Resignation: Mary Ann Gray, Ph.D., resigned as a member of the Board of Directors effective March 4, 2024. The Company stated the resignation did not result from any disagreement regarding operations, policies, or practices.
- Bylaw Amendments: On February 29, 2024, the Board adopted amended and restated bylaws to eliminate the classified (staggered) Board structure. Previously, directors served staggered three-year terms. Moving forward, all directors will be elected annually to one-year terms commencing at the 2024 annual meeting of shareholders.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors. The document notes that the summary of the Amended and Restated Bylaws is qualified in its entirety by reference to the full text attached as Exhibit 3.1.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Dr. Gray's resignation.
- Review the full text of the Amended and Restated Bylaws (Exhibit 3.1) to understand the specific administrative changes and the new annual election process.
- Confirm the date and agenda for the 2024 annual meeting of shareholders where the new director election structure will take effect.